Post-operative radiotherapy for ductal carcinoma in situ of the breast

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2009, Pages

  Goodwin, Annabel ^a   Parker, Sharon ^b   Ghersi, Davina ^b   Wilcken, Nicholas ^a  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Breast neoplasms *radiotherapy; surgery ; Carcinoma in situ *radiotherapy; surgery ; Carcinoma, ductal, breast *radiotherapy; surgery ; Combined modality therapy methods ; Female; Humans; Mastectomy, segmental; Radiotherapy adverse effects ; Randomized controlled trials as topic

Indexed keywords

BREAST DUCT; CANCER INVASION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CLINICAL TRIAL; DISEASE COURSE; HUMAN; INTRADUCTAL CARCINOMA; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; QUALITY OF LIFE; RADIATION DOSE; RADIATION INJURY; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; FEMALE; META ANALYSIS; MULTIMODALITY CANCER THERAPY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEGMENTAL MASTECTOMY; ADVERSE EFFECTS; PARTIAL MASTECTOMY;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 70049102551     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD000563.pub6     Document Type: Review

References (39)

1. EORTC 2006 {published data only} * Bijker N, Meijnen P, Peterse J, Bogaerts J, Van Hoorebeeck I, Julien JP, et al.Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: Ten-year results of European Organisation for Research and Treatment of Cancer Randomized Phase III Trial 10853, a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Journal of Clinical Oncology 2006;24(21):3381-7.
2. Bijker N, Peterse JL, Duchateau L, Julien JP, Fentiman IS, Duval C, et al.Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: Analysis of European Organization for Research and Treatment of Cancer Trial 10853. Journal of Clinical Oncology 2001;19(8):2263-71.
3. Bijker N, Peterse JL, Fentiman IS, Julien JP, Hart AAM, Avril A, et al.Effects of patient selection on the applicability of results from a randomised clinical trial (EORTC 10853) investigating breast-conserving therapy for DCIS. British Journal of Cancer 2002;87: 615-20.
4. Bijker N, Rutgers EJT, Peterse JL, Fentiman IS, Julien JP, Duchateau L, van Dongen JA. Variations in diagnostic and therapeutic procedures in a multicentre, randomized clinical trial (EORTC 10853) investigating breast-conserving treatment for DCIS. European Journal of Surgical Oncology 2001;27:135-40.
5. Fentiman IS, Julien JP, Mignolet F. EORTC trial 10853: treatment options for completely excised ductal carcinoma of the breast. European Journal of Surgical Oncology 1993;19:499.
6. Fentiman IS, Julien JP, van Dongen JA, van Geel B, Chetty U, Coibion M. Reasons for non-entry of patients with DCIS of the breast into a randomised trial (EORTC 10853). European Journal of Cancer 1991;27(4):450-52.
7. Julien JP, Biijker N, Fentiman IS, Peterse JL, Delledonne V, Rouanet P, et al.Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. Lancet 2000;355:529-33.
8. NSABP 2001 {published data only} Fisher B, Dignam J, Wolmark N, Mamounas E, Constantino J, Poller W, et al.Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings form the National Surgical Adjuvant Breast and Bowel Project B-17. Journal of Clinical Oncology 1993;16(2):441-52.
9. * Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W, et al.Lumpectomy and radiation therapy for the treatment of intraduct breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B17. Journal of Clinical Oncology 1998;16(2):441-52.
10. Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. Seminars in Oncology 2001;28 (4):400-18.
11. Fisher ER, Costantino J, Fisher B, Palekar A S, Redmond C, Mamounas E. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B17. Cancer 1995;75 (6):1310-9.
12. Fisher ER, Dignam J, Tan-Chiu E, Costantino J, Fisher B, Paik S, et al.Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight year update of Protocol B17. Cancer 1999; 86(3):429-38.
13. Nol G, Proudhom MA, Mazeron JJ. [Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17]. Cancer Radiothèrapie: Journal de la Sociètè Française de Radiothèrapie Oncologique 1999;3(4):342-3.
14. SweDCIS 2008 {published data only} Emdin SO, Granstrand B, Ringberg AR, Sandelin K, Arnesson LG, Nordgren H, et al.SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offerred mammography screening. Acta Oncologica 2006;45:536-43.
15. * Holmberg L, Garmo H, Granstrand B, Ringberg A, Arnesson LG, Sandelin K, et al.Absolute risk reductions for local recurrence after post operative radiotherapy after sector resection for ductal carcinoma in situ. Journal of Clinical Oncology 2008;26(8): 1247-52.
16. Ringberg A, Nordgren H, Thorstensson S, Idvall I, Garmo H, Granstrand B, et al.Histopathological risk factors for ipsilateral breast events after breast conserving treatment for ductal carcinoma in situ of the breast - Results from the Swedish randomised trial. European Journal of Cancer 2007;43:291-8.
17. UKCCCR 2003 {published data only} George WD, Houghton J, Cuzick J, Forbes J. Radiotherapy and tamoxifen following complete local excision (CLE) in the management of ductal carcinoma in situ (DCIS): Preliminary results from the UK DCIS trial. Proceedings of the American Society of Clinical Oncology. 2000; Vol. Abstract No 270.
18. Stewart HJ. The UKCCCR treatment trial in localised DCIS of the breast [abstract]. British Journal of Cancer 1990 Suppl XII;62:34.
19. * UK Coordinating Committee on Cancer Research (UKCCCR). Radiotherapy and tamoxifen in women with completely excised carcinoma in situ of the breast in the UK, Australia and New Zealand: randomised controlled trial. Lancet 2003;362:95-102.
20. Assertohn 1999 {published data only} Assersohn L, Powles TJ, Ashley S, Nash AG, Neal AJ, Sacks N, et al.Local relapse in primary breast cancer patients with unexcised positive surgical margins after lumpectomy, radiotherapy and chemoendocrine therapy. Annals of Oncology 1999;10(12):1451-5.
21. Clark 1992 {published data only} Clark RM, McCulloch PB, Levine MN, Lipa M, Wilkinson RH, Mahoney LJ, et al.Randomized clinical trial to assess the effectiveness of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer. Journal of the National Cancer Institute 1992;84(9):683-9.
22. Goel V 1997 {published data only} Goel V, Olivotto I, Hislop TG, Sawka C, Coldman A, Holowaty EJ. Patterns of initial management of node-negative breast cancer in two Canadian provinces. British Columbia/Ontario Working Group. Canadian Medical Association Journal 1997;156:25- 35.
23. Lee 1994 {published data only} Lee RPF, Vincenti A, Buchanan R, Rainsbury RM. Selective radiotherapy following wide local excision of breast cancer: Early results of a randomized trial (abstract). European Journal of Cancer 1994;30 Suppl 2:42.
24. Silverstein 1991 {published data only} Silverstein MJ, Waisman JR, Gierson ED, Colburn W, Gamagami P, Lewinsky BS. Radiation therapy for intraductal carcinoma. Is it an equal alternative?. Archives of surgery 1991;126(4):424-8.
25. NCT00077168 {published and unpublished data} Adjuvant radiation therapy compared with observation after surgery in treating women with estrogen receptor positive or progesterone receptor positive ductal carcinoma In situ of the breast who are receiving tamoxifen or anastrozole.. Ongoing study February 2004.
26. RTOG 98 {published and unpublished data} Phase III trial of observation +/- tamoxifen versus RT +/- tamoxifen for good risk ductal carcinoma in situ (DCIS) of the female breast.. Ongoing study December 1999.
27. Burstein 2004 Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in situ of the breast. New England Journal of Medicine 2004;350:1430-41.
28. Cochrane Collaboration 2008 Higgins JPT, Green S (editors). The Cochrane Collaboration, 2008. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0.. Th Cochrane Collaboration, Updated February 2008.
29. EBCTCG 2000 Early Breast Cancer Trialists' Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: An overview of the randomised trials. Lancet 2000; 9217(355):1757-70.
30. Harris 1992 Harris JR, Lippman ME, Veronesi U, Willett W. Breast cancer (second of three parts). New England Journal of Medicine 1992;327 (6):390-8.
31. Levine 2001 Levine M. Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Clinical practice guidelines for the care and treatment of breast cancer: the management of ductal carcinoma in situ (summary of the 2001 update). Canadian Medical Association Journal 2001;165(7):912-3.
32. Millikan 1995 Millikan R, Dressler L, Geradts J, Graham M. The need for epidemiologic studies of in-situ carcinoma of the breast. Breast Cancer Research and Treatment 1995;35:65-77.
33. Mokbel 2002 Mokbel K. Towards optimal management of ductal carcinoma in situ of the breast. European Journal of Surgical Oncology 2002;29: 191-7.
34. Morrow 2002 Morrow M, Strom EA, Bassett LW, Dershaw DD, Fowble B, Harris JR, et al.Standard for the management of ductal carcinoma in situ of the breast (DCIS). A Cancer Journal for Clinicians 2002;52(5): 256-76.
35. NBCC 2003 National Breast Cancer Centre. The clinical management of ductal carcinoma in situ, lobular carcinoma in situ and atypical hyperplasia of the breast. 1. National Breast Cancer Centre, 2003.
36. Parmar 1998 Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815-34.
37. Reaby 1998 Reaby L. The quality and coping patterns of women's decision-making regarding breast cancer surgery. Psycho-Oncology 1998;7: 252-62.
38. Silverstein 1998 Silverstein MJ, Lagios MD, Martino S, Lewinsky BS, Craig PH, Beron PJ, et al.Outcome after invasive local recurrence in patients with ductal carcinoma in situ of the breast. Journal of Clinical Oncology 1998;16:1367-73.
39. Solin 2001 Solin LJ, Fourquet A, Vicini FA, et al.Salvage treatment for local recurrence after breast-conserving surgery and radiation as initial treatment for mammographically detected ductal carcinoma in situ of the breast. Cancer 2001;91:1090-7.